trial

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCTId NCT01429740
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 29 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2011-08
Primary completion
2011-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-05180999

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE1
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
PF-05180999
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication